Free Trial
NASDAQ:ATYR

aTyr Pharma Q1 2024 Earnings Report

aTyr Pharma logo
$5.23 -0.38 (-6.77%)
Closing price 04:00 PM Eastern
Extended Trading
$5.27 +0.04 (+0.76%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

aTyr Pharma EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.24
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

aTyr Pharma Revenue Results

Actual Revenue
$0.24 million
Expected Revenue
$0.11 million
Beat/Miss
Beat by +$130.00 thousand
YoY Revenue Growth
N/A

aTyr Pharma Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 2, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

aTyr Pharma's Q3 2025 earnings is scheduled for Tuesday, August 12, 2025

aTyr Pharma Earnings Headlines

aTyr Pharma (NASDAQ:ATYR) Stock Rating Lowered by Wall Street Zen
Amazon’s big Bitcoin embarrassment
Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.
See More aTyr Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email.

About aTyr Pharma

aTyr Pharma (NASDAQ:ATYR) engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

View aTyr Pharma Profile

More Earnings Resources from MarketBeat